Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MEDITOR EUROPEAN MASTER FUND LTD reports 19.000.000 shares or 5,3% stake 2012/08/20
http://whalewisdom.com/schedule13d/view/65371
but also a lot of demand. time is on our (long) side.
two separate 100k sh buys @1.76. nice
just like I said
don't agree with you either. there are so many possibilties for off label use like every CHOP, CEOP, COMP etc. scheme.
many oncologists rather try an off label use if they see a possible advantage than sticking to their old schemes with worse odds.
therefore you need some well educated sales staff having some commercial experience in selling chemotherapeutics to get Marqibo out in the field and running. that's what big pharma has ...
sounds reasonable. hope you're right. would love to see them coming along with a really big partner...
the thing that I'm a little worried about is SD sayin "We're kind of working on parallel paths."
what kind of strategy is this? IMO you can't go out there, recruit some sales force and sit at the table with big pharma at the very same time.
that's spending time and money for nothing.
I just would prefer him clearly stating "this way or the other" and not both of them.
and for sure I rather would prefer partnership than going their street all alone
EASTERN CAPITAL LIMITED reports 11,341,083 shares or 6,34% stake in EXEL filed 2012/08/17
http://whalewisdom.com/schedule13d/view/65370
nice
just in case this bear raid you're talking about ever happens, i'm sittin down on the bid @1.17 buyin more shares
bought back today 4k shares @1.53 after i sold @1.31 from my initial position.
too bad for me the gap didn't fill. now i have 1k shares less than i had before but it looks too good to let it go without me.
GLTA
CYTK-4 Buy ratings past month
from another board. THX to Cjboro
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=78499264
errett, i bought talon @0,77 back in early 2010 once it was hana bio.
so, i don't doubt your numbers - i doubt that WP and Deerfield will convert. they will never be able go unload such a mass of shares ATM and therefore they won't get the profit they're calculating at.
i believe in the bigger picture since i had the chance to sell for a nice gain a few times in the last two years and didn't do it.
good luck to you though
you guys really like to highlight the dilution boogeyman, don't you...
SA is just a joke.
every fart with a keyboard can post a so called "DD" there.
everyone who is following this red-acre scam and his "friends and family private equity funds" (whatever that really means - maybe a 2000$ fund lol) is either lazy, dumb or both
http://seekingalpha.com/article/794311-knight-capital-s-rescue-deal-a-lesson-for-biotech-investors
sorry, but that won't make any sense. the cat's already out of the box, so why should it be halted?
with the 10 SMA broken and looking at the last daily candles i have to agree.
got my stop filled yesterday @1,31 and am now waiting for another entry - obviously i hope for a lower buy-in than my stop has been
Ascendiant Capital Markets initiates ECTE coverage with a buy recommendation
price target 2$
http://online.wsj.com/mdc/public/page/2_3024-UpgradesDowngrades.html
running gaps normally stay unclosed as long as the value is substantial or the hype is lasting.
GLTA
another reason for the 3 month delay that occured back in may could have been the initiation of the HALLMARQ study which happened later than the first announced PDUFA date - in june.
maybe the FDA wanted to get sure that the study has already started before they make their decision. just my thoughts, but would be very positive for TLON...
hope so too...
it's gettin' interesting. volume before price as $heff states. so let's get some real volume.
AEGIS CAPITAL CORP. initiated coverage with a "buy" rating and a 2.50$ target within 18 months.
here's the link: http://bit.ly/MI4p3k
GLTA
joined the club @0,715 with 5k shares.
bid is strong btw 0,70 and 0,71 all day on a deeply red trading day. hoping for a 0,75 break soon.
GLTA
maybe some stop loss catching going on...
grabbed some @1.53 - the SMA50
GLTA
imo, there won't be any dilution. TLON tapped around 3mill. from their deal with warburg & deerfield. so the financing is done and they can go on waiting for approval.
TLON.. $1.35 they did a small financing of ~3 million $ with Warburg Pincus & Deerfield using the Series A-3 Preferred Stock agreement.
http://ih.advfn.com/p.php?pid=nmona&article=52999251
http://ih.advfn.com/p.php?pid=nmona&article=52999214
IMO dilution is not an issue before the PDUFA date in august. Deerfield should be done selling in a few trading days, if the volume stays that high.
green future for all TLON longs keeps lurking around the corner.
GLTA
DCTH .. $1.44
worth a look after closing a ~21$ million financing with shares @ 1.50$ combined with warrants @ 1.65$
TLON (0,765) announced first patient enrolled - HALLMARQ
http://finance.yahoo.com/news/talon-therapeutics-announces-enrollment-dosing-120000533.html
well said... thumbs up
me too. 12k @ 0,77
GLTA
yeah... you're right about the presentations. talon suggested the acceptance/denial late 2011 at first and then 1Q 2012.
the heck with it... just another couple of month
The point is Talon never requested for priority review.
"A request for Priority Review must be made by the drug company. It does not affect the length of the clinical trial period. FDA determines within 45 days of the drug company’s request whether a Priority or Standard Review designation will be assigned."
Fast track status and accelerated review both don't really affect the timeline of being reviewed by the FDA.
www.fda.gov/forconsumers/byaudience/forpatientadvocates/speedingaccesstoimportantnewtherapies/ucm128291.htm
So, Talon never told us that they are asking for a 6-month timeframe for a PDUFA date after submission. They always taked about fast track status and accelerated approval but they never lost a word about priority review.
many took that for granted...